COVID-19 Resource Center
COVID-19 Resource Center
Source/Disclosures
Disclosures: Fincher is president of the ACP. Please see the study for all other authors’ relevant financial disclosures.
October 06, 2020
2 min read
Save

ACP recommends remdesivir for moderate, severe COVID-19

Source/Disclosures
Disclosures: Fincher is president of the ACP. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In new Rapid Living Practice Points published in the Annals of Internal Medicine, the ACP announced that current evidence suggests there is a net benefit associated with the use of remdesivir in patients with COVID-19.

“With remdesivir there is evidence of benefit with shorter duration treatment for patients with both moderate or severe COVID-19, which is positive news in the search for treatments of patients with COVID-19,” ACP President Jacqueline W. Fincher, MD, said in a press release.

ACP recommendations on remdesivir for COVID-19
Reference: Qaseem A, et al. Ann Intern Med. 2020;doi:10.7326/M20-5831.

The practice points, developed by the ACP’s Scientific Medical Policy Committee (SMPC), were based on a systematic review conducted by the U.S. Department of Veteran Affairs.

In the paper, SMPC members said that research comparing 5-day and 10-day treatment with remdesivir showed that the 5-day treatment period may slightly reduce mortality and result in slightly increased clinical improvement compared with the 10-day treatment. They also found that 5-day treatment with remdesivir may result in fewer adverse events than the 10-day treatment but may not lead to a decrease in serious adverse events.

Jacqueline W. Fincher
Jacqueline W. Fincher

SMPC members did not identify an effect on other critical outcomes — including recovery and hospitalization time — and important outcomes — including time to recovery, invasive ventilation, ECMO and adverse events that were not serious — in either 5-day or 10-day treatment periods in moderate COVID-19.

Although more research is needed, SMPC members said that evidence suggests a 5-day treatment period is as effective as a 10-day treatment period in patients with severe COVID-19 who do not require ventilation or ECMO at baseline.

However, they also found evidence that patients placed on mechanical ventilation or ECMO at day 5 may benefit from extending the remdesivir treatment period to 10 days compared with discontinuing treatment after 5 days.

Based on these findings, the ACP recommends:

  • 5-day treatment with remdesivir in patients with moderate COVID-19;
  • 5-day treatment with remdesivir in patients with severe COVID-19 who do not require ventilation or EMCO; and
  • consider extending remdesivir treatment to 10 days in patients with severe COVID-19 who require ventilation or ECMO during initial 5-day treatment period.

The ACP noted that there are currently numerous studies on remdesivir in COVID-19 that are planned or ongoing, so the practice points will be reviewed continually, with updates planned every 2 months through December 2021. However, the SMPC will assess the priority of the topic and the state of evidence continuously and may choose to modify the 2-month update interval.

As there are still significant research gaps surrounding remdesivir treatment in COVID-19, Fincher said “additional rigorous studies are needed to assess the benefits and harms of using remdesivir to treat patients with COVID-19.”

References:

Qaseem A, et al. Ann Intern Med. 2020;doi:10.7326/M20-5831.

Press release.